{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:05:14Z","timestamp":1784613914766,"version":"3.55.0"},"reference-count":99,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Hematopoietic stem cell transplantation (HSCT) and chimeric antigen receptor T-cell (CAR-T) therapy are two major therapeutic approaches for hematologic malignancies. HSCT can provide durable disease control through conditioning-induced tumor cytoreduction, immune reconstitution, and graft-versus-leukemia effects, whereas CAR-T therapy provides antigen-specific antitumor activity and has reshaped the treatment landscape for relapsed or refractory leukemia, lymphoma, and multiple myeloma (MM). Despite these advances, both therapeutic approaches continue to face multiple challenges. HSCT is limited by disease relapse and transplant-related complications, while CAR-T therapy is challenged by antigen escape, limited persistence, and treatment-related toxicities. Increasing clinical experience suggests that HSCT and CAR-T therapy should not be viewed as competing strategies, but rather as complementary therapeutic approaches whose value depends on disease characteristics, depth of response, immune recovery, and transplant feasibility. On the one hand, CAR-T therapy can reduce tumor burden before transplantation, be incorporated into modified conditioning regimens, or be used after allogeneic HSCT (allo-HSCT) as prophylactic, preemptive, or salvage cellular therapy. On the other hand, HSCT can consolidate CAR-T-induced remission, provide hematopoietic support in selected settings, and create a post-transplant immune environment that may facilitate subsequent CAR-T-cell therapy. In this review, we summarize the current evidence for HSCT\u2013CAR-T integration in leukemia, lymphoma, and MM. We discuss major integration strategies, including HSCT after CAR-T therapy, CAR-T-assisted conditioning, autologous stem cell transplantation (ASCT)\u2013CAR-T sequential strategies, and CAR-T therapy after allo-HSCT. We aim to help match appropriate patients to the most suitable HSCT\u2013CAR-T strategies and thereby improve clinical decision-making.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1898336","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:35:58Z","timestamp":1784612158000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["HSCT and CAR-T: a power couple\u2014but who serves whom?"],"prefix":"10.3389","volume":"17","author":[{"given":"Shuai","family":"Yao","sequence":"first","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Mo","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghua","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heyang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-031-44080-9","volume-title":"The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies","author":"Sureda","year":"2024"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-025-02701-3","article-title":"Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations","volume":"60","author":"Greco","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(23)00342-3","article-title":"Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological Malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"11","author":"Penack","year":"2024","journal-title":"Lancet Haematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25108","article-title":"Potent anti-leukemia activities of humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"93","author":"Cao","year":"2018","journal-title":"Am J Hematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-025-01708-z","article-title":"CD19 CAR-T in relapsed t (8,21) AML: a single-center prospective phase II clinical trial","volume":"18","author":"Yin","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1491341","article-title":"Utilization of donor CLL-1 CAR-T cells for the treatment of relapsed of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1454614","article-title":"Case report: Successful combination of CLL1 CAR-T therapy and hematopoietic stem cell transplantation in a 73-year-old patient diagnosed with refractory acute myeloid leukemia","volume":"15","author":"Zhao","year":"2024","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024861","article-title":"Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia","volume":"145","author":"Lu","year":"2025","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1389227","article-title":"Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed\/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission","volume":"15","author":"Miao","year":"2024","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","article-title":"First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia","volume":"15","author":"Jin","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jtct.2024.11.009","article-title":"CD7 CART therapy bridging allo-HSCT remarkably improves long-term DFS in refractory\/relapsed T-ALL\/LBL","volume":"31","author":"Li","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25582","article-title":"Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial","volume":"94","author":"Jiang","year":"2019","journal-title":"Am J Hematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00262-021-03009-z","article-title":"Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia","volume":"71","author":"Zhang","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40364-023-00451-2","article-title":"CAR-T cell therapy followed by allogenic hematopoietic stem cell transplantation yielded comparable outcome between Ph like ALL and other high-risk ALL","volume":"11","author":"Dai","year":"2023","journal-title":"biomark Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007423","article-title":"Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells","volume":"7","author":"Lamble","year":"2023","journal-title":"Blood Adv"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2025.02.006","article-title":"Sequential allogeneic HSCT after CAR-T therapy for relapsed\/refractory acute lymphoblastic leukemia patients: a long-term follow-up result","volume":"78","author":"Yang","year":"2025","journal-title":"J Adv Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.605766","article-title":"Integrating CAR T-cell therapy and transplantation: Comparisons of safety and long-term efficacy of allogeneic hematopoietic stem cell transplantation after CAR T-cell or chemotherapy-based complete remission in B-cell acute lymphoblastic leukemia","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19445","article-title":"A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T-cell acute lymphoblastic leukaemia\/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen receptor T-cell therapy","volume":"204","author":"Cao","year":"2024","journal-title":"Br J Haematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.934442","article-title":"Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: Pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell therapy versus chemotherapy","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-399287","article-title":"Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation","volume":"120","author":"Gokbuget","year":"2012","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012727","article-title":"Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy","volume":"139","author":"Leahy","year":"2022","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2024.103471","article-title":"Point of care CD19 chimeric antigen receptor (CAR) T-cells for relapsed\/refractory acute myeloid leukemia (AML) with aberrant CD19 antigen expression","volume":"72","author":"Danylesko","year":"2024","journal-title":"Curr Res Transl Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1461908","article-title":"Naturally selected CD7-directed CAR-T bridging allo-HSCT in refractory acute myeloid leukemia: a case report and review","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16982","article-title":"CAR-T therapy bridging to allogeneic HSCT provides durable molecular remission of Ph(+) mixed phenotype acute leukaemia with minimal residual disease","volume":"191","author":"Kong","year":"2020","journal-title":"Br J Haematol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3324\/haematol.2022.281242","article-title":"Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma","volume":"108","author":"Zurko","year":"2023","journal-title":"Haematologica"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000593","article-title":"Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy","volume":"3","author":"Shadman","year":"2019","journal-title":"Blood Adv"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001956","article-title":"Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents","volume":"4","author":"Roeker","year":"2020","journal-title":"Blood Adv"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.jtct.2024.08.024","article-title":"Effects of consolidation therapy with autologous hematopoietic stem cell transplantation after BCMA-CAR T-cell therapy on the survival of patients with relapsed or refractory multiple myeloma","volume":"30","author":"Zhou","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1182\/blood-2023-182058","article-title":"Consolidation with first and second allogeneic transplants in adults with relapsed\/refractory B-ALL following response to CD19CAR T cell therapy","volume":"30","author":"Aldoss","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023699","article-title":"How I use next-generation sequencing-MRD to plan approach and prevent relapse after HCT for children and adults with ALL","volume":"144","author":"Muffly","year":"2024","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023009856","article-title":"Next-generation sequencing-based MRD in adults with ALL undergoing hematopoietic cell transplantation","volume":"7","author":"Liang","year":"2023","journal-title":"Blood Adv"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01903-3","article-title":"Allogeneic stem cell transplantation combined with conditioning regimen including donor-derived CAR-T cells for refractory\/relapsed B-cell lymphoma","volume":"58","author":"Yang","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000233","article-title":"Donor-derived CAR-T cells serve as a reduced-intensity conditioning regimen for haploidentical stem cell transplantation in treatment of relapsed\/refractory acute lymphoblastic leukemia: Case report and review of the literature","volume":"41","author":"Zhang","year":"2018","journal-title":"J Immunother"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.965932","article-title":"Case report: Successful engraftment of allogeneic hematopoietic stem cells using CAR-T cell therapy as the conditioning regimen in R\/R Ph(+) B cell acute lymphoblastic leukemia","volume":"13","author":"Han","year":"2022","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.914","article-title":"Stable engraftment, as well as graft versus host disease-free and relapse-free survival brought by the combination of CD7 targeted universal chimeric antigen receptor-T, and donor hemopoietic stem cells: Indication of a case report","volume":"5","author":"Li","year":"2024","journal-title":"EJHaem"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2313812","article-title":"Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis","volume":"390","author":"Hu","year":"2024","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.268839","article-title":"Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: Can we recommend \"when and for whom\" in 2021","volume":"106","author":"Gagelmann","year":"2021","journal-title":"Haematologica"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: What we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19524","article-title":"Success of donor-derived CAR-T cells after failure of autologous CD19 CAR-T cells (tisagenlecleucel) in B-cell acute lymphoblastic leukaemia","volume":"205","author":"Dourthe","year":"2024","journal-title":"Br J Haematol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: First-in-human, phase I trial","volume":"39","author":"Pan","year":"2021","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-023-01427-3","article-title":"Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia","volume":"16","author":"Tan","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01358","article-title":"Donor-derived CD123-targeted CAR T cell serves as a RIC regimen for haploidentical transplantation in a patient with FUS-ERG+ AML","volume":"9","author":"Yao","year":"2019","journal-title":"Front Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2024.10.005","article-title":"A successful haploidentical transplantation without conditioning regimen for a relapsed\/refractory multiple myeloma patient after chimeric antigen receptor T-cell therapy","volume":"27","author":"Dai","year":"2025","journal-title":"Cytotherapy"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1219872","article-title":"Case report: Unedited allogeneic chimeric antigen receptor T cell bridging to conditioning-free hematopoietic stem cell transplantation for a child with refractory Burkitt lymphoma","volume":"14","author":"Yang","year":"2023","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(24)00077-2","article-title":"Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management","volume":"11","author":"Rejeski","year":"2024","journal-title":"Lancet Haematol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-1040","article-title":"Interim phase 1 study of sequential CD7 CAR T-cell therapy and haploidentical HSCT without GVHD prophylaxis in patients with relapsed\/refractory CD7-positive hematologic Malignancies","volume":"146","author":"Yang","year":"2025","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","first-page":"120505","DOI":"10.1172\/jci.insight.120505","article-title":"Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma","volume":"3","author":"Garfall","year":"2018","journal-title":"JCI Insight"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285613","article-title":"Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy","volume":"110","author":"Mercadal","year":"2025","journal-title":"Haematologica"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-686725","article-title":"Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-022-00924-0","article-title":"Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT","volume":"7","author":"Wei","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B60","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00262-024-03855-7","article-title":"Clinical outcomes of chimeric antigen receptor T-cell therapy following autologous hematopoietic stem cell transplantation in 38 patients with refractory\/relapsed primary or secondary central nervous system lymphoma","volume":"74","author":"Wu","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B61","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s40164-024-00538-y","article-title":"CD19\/CD22 CAR-T-cell cocktail therapy following autologous transplantation is an optimizing strategy for treating relapsed\/refractory central nervous system lymphoma","volume":"13","author":"Zhou","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/2900310","article-title":"The autologous hematopoietic stem cells transplantation combination-based chimeric antigen receptor T-cell therapy improves outcomes of relapsed\/refractory central nervous system B-cell lymphoma","volume":"2022","author":"Xue","year":"2022","journal-title":"J Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26486","article-title":"Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma","volume":"97","author":"Shi","year":"2022","journal-title":"Am J Hematol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-025-02571-7","article-title":"Long-term follow-up demonstrates the curative potential of dual CD19\/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"11","author":"Mao","year":"2026","journal-title":"Signal Transduct Target Ther"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.bcd-24-0317","article-title":"Long-term therapy outcomes of CD19\/22 CAR T cell alone or with autologous stem cell transplantation for relapsed\/refractory DLBCL","volume":"7","author":"Zhang","year":"2026","journal-title":"Blood Cancer Discov"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad118","article-title":"Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells","volume":"25","author":"Karschnia","year":"2023","journal-title":"Neuro Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.3390\/cancers16091722","article-title":"Adverse reactions in relapsed\/refractory B-cell lymphoma administered with chimeric antigen receptor T cell alone or in combination with autologous stem cell transplantation","volume":"16","author":"Lin","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1098815","article-title":"Double systemic cytokine release syndrome following sequential infusion of anti-CD22 and anti-CD19 chimeric antigen receptor T cells after autologous hematopoietic stem cell transplantation for a central diffuse large B-cell lymphoma patient: A case report and literature review","volume":"14","author":"Zheng","year":"2023","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.01.001","article-title":"SOHO state of the art updates and next questions: Will CAR-T replace ASCT in NDMM","volume":"24","author":"Jurgens","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B73","doi-asserted-by":"publisher","first-page":"4766","DOI":"10.1182\/blood-2024-207687","article-title":"5-year follow-up of combined infusion of anti-CD19 and anti-BCMA CAR-T after ASCT for high-risk newly diagnosed multiple myeloma","volume":"144","author":"Shi","year":"2024","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010687","article-title":"Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed\/refractory multiple myeloma","volume":"13","author":"Jin","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.12.019","article-title":"CD19 CAR-T with axicabtagene ciloleucel in R\/R large B-cell lymphoma with\/without prior autologous stem cell transplant","volume":"25","author":"Chen","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025705","article-title":"How I treat AML relapse after allogeneic HSCT","volume":"145","author":"Gooptu","year":"2025","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2091","article-title":"Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse","volume":"4","author":"Kharfan-Dabaja","year":"2018","journal-title":"JAMA Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-752121","article-title":"Posttransplant chimeric antigen receptor therapy","volume":"131","author":"Smith","year":"2018","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01056-6","article-title":"Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant","volume":"35","author":"Zhang","year":"2021","journal-title":"Leukemia"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26160","article-title":"Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation","volume":"96","author":"Liu","year":"2021","journal-title":"Am J Hematol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13045-024-01626-6","article-title":"Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation","volume":"17","author":"Zhang","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102377","article-title":"Donor-derived anti-CD19 CAR T cells GC007g for relapsed or refractory B-cell acute lymphoblastic leukemia after allogeneic HSCT: a phase 1 trial","volume":"67","author":"Luo","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01140-6","article-title":"Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation","volume":"56","author":"Hua","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s11596-023-2746-1","article-title":"Donor-derived CD19 CAR-T cells versus chemotherapy plus donor lymphocyte infusion for treatment of recurrent CD19-positive B-ALL after allogeneic hematopoietic stem cell transplantation","volume":"43","author":"Tan","year":"2023","journal-title":"Curr Med Sci"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1191382","article-title":"Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant","volume":"14","author":"Cao","year":"2023","journal-title":"Front Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2024.05.021","article-title":"Efficacy and risk of donor-derived CAR-T treatment of relapsed B-cell acute lymphoblastic leukemia after hematopoietic stem cell transplantation","volume":"26","author":"Deng","year":"2024","journal-title":"Cytotherapy"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.750218","article-title":"Efficacy and safety of chimeric antigen receptor T cells in acute lymphoblastic leukemia with post-transplant relapse","volume":"11","author":"Ding","year":"2021","journal-title":"Front Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.573822","article-title":"Acute graft-versus-host disease after humanized anti-CD19-CAR T therapy in relapsed B-ALL patients after allogeneic hematopoietic stem cell transplant","volume":"10","author":"Liu","year":"2020","journal-title":"Front Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02467-5","article-title":"Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study","volume":"39","author":"Orti","year":"2025","journal-title":"Leukemia"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1500177","article-title":"GVHD after CAR T-cell therapy post allogeneic hematopoietic cell transplantation - successfully treated by extracorporeal photopheresis","volume":"15","author":"Farid","year":"2024","journal-title":"Front Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02251-5","article-title":"Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation","volume":"38","author":"Lu","year":"2024","journal-title":"Leukemia"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1191912","article-title":"Novel strategies to prevent and overcome relapse after allogeneic hematopoietic cell transplantation in acute lymphoblastic leukemia","volume":"14","author":"Hodroj","year":"2023","journal-title":"Front Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01351-w","article-title":"Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation","volume":"36","author":"Zhao","year":"2022","journal-title":"Leukemia"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217264","article-title":"Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update","volume":"605","author":"Wang","year":"2024","journal-title":"Cancer Lett"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(24)00098-x","article-title":"Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological Malignancies: basic considerations and best practice recommendations from the EBMT","volume":"11","author":"Pagliuca","year":"2024","journal-title":"Lancet Haematol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013290","article-title":"Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia","volume":"139","author":"Gaballa","year":"2022","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-017-0405-3","article-title":"Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell Malignancies","volume":"10","author":"Liu","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000016498","article-title":"Preventive infusion of donor-derived CAR-T cells after haploidentical transplantation: Two cases report","volume":"98","author":"Zhang","year":"2019","journal-title":"Med (Baltimore)"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.07.018","article-title":"Best practice considerations by the American Society of Transplant and Cellular Therapy: Infection prevention and management after chimeric antigen receptor T cell therapy for hematological Malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transplant Cell Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1898336\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:35:59Z","timestamp":1784612159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1898336\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":99,"alternative-id":["10.3389\/fimmu.2026.1898336"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1898336","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"article-number":"1898336"}}